Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.58 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630644 | 0.80 | SMPD1 (0.61) | ALOX5 | |
| SCHEMBL5381858 | 0.78 | CYSLTR1 (0.56) | CYSLTR1GPBAR1 | |
| SCHEMBL5112999 | 0.77 | CYSLTR1 (0.58) | CYSLTR1ALOX5APGPBAR1 | |
| SCHEMBL8801078 | 0.76 | CYSLTR1 (0.64) | CYSLTR1ALOX5APGPBAR1 | |
| SCHEMBL5382515 | 0.75 | CYSLTR1 (0.52) | CYSLTR1ALOX5APGPBAR1 | |
| SCHEMBL8708062 | 0.75 | SMPD1 (0.46) | — | |
| SCHEMBL9582305 | 0.74 | CYSLTR1 (0.61) | CYSLTR1ALOX5APGPBAR1 | |
| SCHEMBL3271439 | 0.74 | CYSLTR1 (0.76) | CYSLTR1ALOX5APGPBAR1ALOX5 | |
| SCHEMBL25213744 | 0.74 | CYSLTR1 (0.78) | CYSLTR1ALOX5APGPBAR1 | |
| SCHEMBL9130463 | 0.74 | CYSLTR1 (1.00) | CYSLTR1ALOX5APGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241785-B2 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-10 | — | — | US | disclosed |
| US-7179823-B1 | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-20 | — | — | US | disclosed |
| EP-1457490-A1 | 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity | Takeda Chemical Industries, Ltd. (JP) | 2004-09-15 | — | — | EP | disclosed |
| EP-1228067-B1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1394154-A1 | FIVE-MEMBERED HETEROCYCLIC ALKANOIC ACID DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1228067-A1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGYLCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001038325-A1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | SLC5A1, AHR, ALOX5 | CYSLTR1 537/4885ALOX5AP 153/4885GPBAR1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.